Award for Bilobil in Poland

The first place in the national competition "Consumer's Laurel 2007" in the category "Drugs for memory improvement" has been won by Krka's Bilobil. As in the last year, also this year Bilobil won the first place in its category.

The award was based on voting by the Polish people. Bilobil turned out to be the most popular drug for memory improvement in Poland. This year Bilobil was also appreciated by pharmacists who awarded it The Product of the Year 2007 within the products for memory improvement. So it appears that Bilobil is the most highly evaluated drug in its group by patients and specialists.

Bilobil was frequently selected by the Polish pharmacists and patients who in the last year awarded it a gold "Consumer's Laurel".

Bilobil was also twice awarded a statuette of Golden Otis.

Bilobil is a drug that contains natural Ginkgo biloba leaf substances which improve the metabolism in brain cells and the supply of oxygen to the brain. The active substances of the extract improve memory and concentration, and are beneficial for life energy. The clinical examination* which was carried out in Otolaryngology Clinic Collegium Medicum in Bydgoszcz proved that the drug improves brain functions, such as memory and the ability to concentrate. Bilobil also efficiently prevents dizziness and tingling in the ears. In 2004 the producer enriched the Bilobil brand in Poland by a new product. Bilobil forte contains a double dose of Ginkgo biloba extracts (80 mg) and is intended for the active part of the population enabling a longer and a more intensive mental effort.

About Krka
Krka is one of the top generic pharmaceutical companies in Europe. For further information, please visit www.krka.si.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...